AstraZeneca closes India R&D shop

Share this article:

AstraZeneca is laying off 168 pharmaceutical employees at the Avishkar R&D site in Bangalore, India. The company said in a statement that the move is in line with its shift to focus on three core areas—oncology; cardiovascular and metabolic; and respiratory, inflammation and autoimmunity.

The Avishkar operation was focused on conditions including TB, malaria and neglected tropical diseases. AstraZeneca will continue to develop Phase-II TB medication AZD5847. The company said it will continue to make its compound library available to open-innovation partnerships.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.